Myriad Genetics, Inc. (MYGN)
Nasdaq: MYGN · In Vitro & In Vivo Diagnostic Substances · Salt Lake City, UT · filing with the SEC since 1996
Filings
295 filings since 2017 beside 604 insider forms · Accelerated filer · read from EDGAR on Nov 13, 2026Due nextAccelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Accelerated filers have 75 days after the fiscal year ends.
by Mar 16, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 35 days after the quarter ended. The proxy statement was last filed Apr 14, 2026.
Filings a yearinsider forms included
6888103941061048989
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 12 times in the last 36 months, the newest Nov 9, 2026.SEC letters: 2 in the last 36 months, the newest Mar 2, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Oct 20, 2026
8-K items 1.01, 7.01, 9.01
Major agreement signed; Investor disclosure (Regulation FD) · Current report
Oct 19, 2026
Sep 16, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Sep 15, 2026
Jun 4, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
40 of 295 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.